Insmed Incorporated filings document formal disclosures for its commercial biopharmaceutical portfolio and respiratory and inflammatory pipeline. Recent Form 8-K reports furnish financial results, investor presentations, Regulation FD materials, clinical-study updates for ARIKAYCE and brensocatib, regulatory approval announcements for BRINSUPRI, and portfolio additions such as INS1148.
The company’s proxy materials describe board elections, executive compensation, equity awards, shareholder voting matters and governance practices. Other current reports document compensatory arrangements, director-transition disclosures, exhibits and Inline XBRL cover-page data tied to Insmed’s Nasdaq-listed common stock.
Sara Bonstein, a former officer of INSMED Inc. (INSM), reported 10,261 common shares for sale through Merrill Lynch, with an approximate sale date of November 3, 2026. The securities information lists an aggregate market value of $1,121,629. Her remarks state that shares were sold to satisfy tax withholding upon vesting of Restricted Stock Units and to cover related broker fees.
INSMED Inc's Corporate Controller Patrick Kevin Kane reported direct ownership of 9,921 Common Stock shares, including restricted stock units (RSUs). The RSUs include 2,258 that vest 25% on each anniversary through the fourth anniversary of the grant, and 5,246 that vest 25% on the Initial Vesting Date and each anniversary of that date until fully vested. He also reported nine direct stock-option positions, with exercise prices from $17.07 to $177.12 and expiration dates from January 6, 2032 through January 2, 2036.
Insmed Incorporated (INSM) reported third-quarter 2026 revenue of $524.4 million, up 268% from a year earlier. BRINSUPRI revenue was $400.1 million, up 29% from the second quarter, and ARIKAYCE revenue was $124.4 million, up 9% year over year. Insmed raised its 2026 revenue guidance to $1.35 billion to $1.4 billion for BRINSUPRI and $460 million to $470 million for ARIKAYCE, raising the lower end of both prior ranges.
Net loss was $100.3 million versus $370.0 million in the prior-year quarter; operating loss was $89.4 million versus $366.0 million. Research and development and selling, general and administrative expenses were $270.0 million and $253.0 million, respectively, compared with $186.4 million each a year earlier; the presentation attributed the increases to the BRINSUPRI launch and clinical pipeline development. Insmed reported approximately $1.1 billion in cash, cash equivalents and marketable securities as of September 30, 2026. It launched BRINSUPRI 25 mg tablets in Japan after approval. The FDA granted priority review to ARIKAYCE’s supplemental application, with a January 28, 2027 target action date.
Insmed (INSM) reported third-quarter 2026 product revenue of $524.4 million, up 268% from $142.3 million a year earlier, and a net loss of $100.3 million, compared with $370.0 million. BRINSUPRI generated $400.053 million and ARIKAYCE $124.375 million in the quarter. For the nine months ended September 30, 2026, net loss was $277.1 million and operating cash used was $348.026 million, versus $687.418 million a year earlier.
At September 30, Insmed held $396.6 million in cash and cash equivalents and $750.1 million in marketable securities. The company said its current funds were sufficient to meet financial needs for at least the next 12 months, while it expects continued operating losses and substantial future cash requirements.
Japan approved BRINSUPRI in August 2026, and Insmed launched it there in October. The FDA accepted the ARIKAYCE supplemental application for priority review, with a January 28, 2027 target action date. Insmed initiated the Phase 3 PALM-PPF study of TPIP in September 2026 and anticipates starting a Phase 3 TPIP study in IPF in the first half of 2027.
INSMED Inc (INSM) director Utpal Koppikar received 6,139 restricted stock units (RSUs) on October 19, 2026, for no consideration. Each RSU represents a contingent right to one common share. The RSUs vest in equal parts on each of the first three one-year anniversaries of the grant date, provided Koppikar remains a director on each vesting date.
INSMED Inc director Paul Hudson acquired 6,139 restricted stock units (RSUs) on October 19, 2026, under the company's Amended and Restated 2019 Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of Common Stock and was granted for no consideration. The reported post-transaction position was 6,139 RSUs. The units vest in equal parts on each of the first three one-year anniversaries, provided Hudson remains a director on each vesting date.
Insmed Incorporated (INSM) appointed Paul Hudson as a Class II director and Utpal Koppikar as a Class I director, effective October 19, 2026. Hudson will serve on the Compensation Committee and Koppikar on the Audit Committee; both are subject to election at the Company’s 2027 Annual Meeting of Shareholders.
Each director will receive an annual cash retainer of $65,000, prorated in the current year based on the appointment date, and restricted stock units with a grant date fair value of approximately $585,000. The RSUs vest in equal parts on each of the first three one-year anniversaries of the award date, provided each recipient remains a director on each vesting date.
Insmed Incorporated announced that Sara Bonstein, its Chief Financial Officer, will step down effective October 30, 2026. She will continue as CFO through that date, and Insmed has begun a search for her successor. The company said her departure is not related to any disagreement over accounting practices, financial statements, internal controls or operations. Bonstein is scheduled to participate in the third-quarter results call on October 29, 2026.
Insmed reaffirmed 2026 revenue guidance of $1.25 billion to $1.40 billion for BRINSUPRI and $450 million to $470 million for ARIKAYCE. The company plans to release third-quarter results on October 29, with an investor call at 8:00 a.m. ET. CEO Will Lewis said Insmed is well positioned, in his view, to reach cash flow positivity next year. He also said the company raised more than $4.2 billion in capital during Bonstein’s nearly seven years at Insmed.